tiprankstipranks
Trending News
More News >

Shanghai Fosun Pharma Strengthens Strategic Oversight with New Committee

Story Highlights
Shanghai Fosun Pharma Strengthens Strategic Oversight with New Committee

Don’t Miss TipRanks’ Half-Year Sale

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an announcement.

Shanghai Fosun Pharmaceutical has established a Strategic Committee under its board of directors to bolster its strategic development and decision-making processes. This committee is tasked with examining the company’s mid and long-term development strategies, significant investment decisions, and other material issues affecting its growth. By reinforcing the scientific nature of decision-making and improving corporate governance, the company aims to enhance investment benefits and decision quality, thereby strengthening its industry positioning.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating in the pharmaceutical industry. The company focuses on developing and manufacturing a wide range of pharmaceutical products and services, with a market emphasis on enhancing its core competitiveness and strategic development.

Average Trading Volume: 7,025,116

Technical Sentiment Signal: Buy

Current Market Cap: HK$65.06B

See more data about 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1